Skip to content
Screener

Twist Bioscience Corporation TWST Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$56.16M-84.8%
GeneDx Holdings logo
GeneDx HoldingsWGS
-$63.57M-885%
TEC
Bio-TechneTECH
$46.54M+77.7%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$46.95M+18.8%
Revvity logo
RevvityRVTY
$48.82M-77.1%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$7.25B+335%
Enterprise value$7.24B+365%
P/S17.7×+13.1×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(In thousands, except per share data)Three months ended March 31, 2026Three months ended March 31, 2025Six months ended March 31, 2026Six months ended March 31, 2025
Income tax expense(43)(175)(296)(271)
Net loss$(44,021)$(39,328)$(74,528)$(70,922)
Other comprehensive loss:
Change in unrealized gain (loss) on investments$(85)$30$(67)$97
Foreign currency translation adjustment17(25)5543
Comprehensive loss$(44,089)$(39,323)$(74,540)$(70,782)
Net loss per share — basic and diluted$(0.71)$(0.66)$(1.21)$(1.19)
Weighted average shares used in computing net loss per share — basic and diluted61,70259,64961,38759,403

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's comprehensive income (loss), net of tax, attributable to parent?
Twist Bioscience Corporation (TWST) reported comprehensive income (loss), net of tax, attributable to parent of -$44.09M in Q1 2026.
How has Twist Bioscience Corporation's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Twist Bioscience Corporation's comprehensive income (loss), net of tax, attributable to parent decreased by 12.1% year-over-year, from -$39.32M to -$44.09M.
What is the long-term trend for Twist Bioscience Corporation's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Twist Bioscience Corporation's comprehensive income (loss), net of tax, attributable to parent has grown at a -15.4% compound annual growth rate (CAGR), from -$151.64M to -$77.76M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as foreign currency adjustments and unrealized gains or losses on securities. It provides a comprehensive view of the company's financial performance beyond traditional net income. Investors use this to evaluate the total economic impact of all financial activities on the company's net worth.

Ask your AI about Twist Bioscience Corporation's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude